TYRA BIOSCIENCES INC
NASDAQ: TYRA (Tyra Biosciences, Inc.)
Kemas kini terakhir: 2 jam lalu24.35
-1.08 (-4.25%)
| Penutupan Terdahulu | 25.43 |
| Jumlah Dagangan | 1,138,496 |
| Harga / Buku (P/B) | 4.94 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.63 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.89% |
| Nisbah Semasa (MRQ) | 22.78 |
| Aliran Tunai Operasi (OCF TTM) | -73.20 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -37.79 M |
| Pulangan Atas Aset (ROA TTM) | -19.00% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Tyra Biosciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.00 |
|
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.69% |
| % Dimiliki oleh Institusi | 108.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alta Partners Management Company, L.P. | 30 Jun 2026 | 3,823,425 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| VERJEE REHAN | 22.01 | - | 972 | 21,394 |
| Jumlah Keseluruhan Kuantiti Bersih | 972 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 21,394 | |||
| Purata Pembelian Keseluruhan ($) | 22.01 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| VERJEE REHAN | Pengarah | 09 Sep 2026 | Beli (+) | 972 | 22.01 | 21,394 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |